key: cord-1014756-x1w9gq5c
authors: Henry, Brandon Michael; Benoit, Stefanie W.; de Oliveira, Maria Helena Santos; Lippi, Giuseppe; Favaloro, Emmanuel J.; Benoit, Justin L.
title: ADAMTS13 activity to von Willebrand factor antigen ratio predicts acute kidney injury in patients with COVID‐19: Evidence of SARS‐CoV‐2 induced secondary thrombotic microangiopathy
date: 2020-12-03
journal: Int J Lab Hematol
DOI: 10.1111/ijlh.13415
sha: f2112267a8b12f628bf1f7f3f668406874a8d800
doc_id: 1014756
cord_uid: x1w9gq5c

INTRODUCTION: Severe COVID‐19 is often compounded by a prothrombotic state that is associated with poor outcomes. In this investigation, we aimed to evaluate ADAMTS13 activity, von Willebrand factor level (VWF:Ag), and the corresponding ADAMTS13 activity/VWF:Ag ratio, in patients with COVID‐19 and for associations with disease progression and acute kidney injury (AKI). METHODS: Patients presenting to the emergency department (ED) with COVID‐19 were enrolled in this prospective, observational study. ADAMTS13 activity and VWF:Ag were measured at index ED visit. The primary endpoint was severe AKI defined by KDIGO stage 2 + 3 criteria, while the secondary endpoint was peak 30‐day COVID‐19 severity. RESULTS: A total of 52 adult COVID‐19 patients were enrolled. Overall, we observed that 23.1% of the cohort had a relative deficiency in ADAMTS13 activity, while 80.8% had elevated VWF:Ag. The ADAMTS13 activity/VWF:Ag ratio was significantly lower in patients with severe AKI (P = .002) and those who developed the severe form of COVID‐19 (P = .020). The ADAMTS13 activity/VWF:Ag ratio was negatively correlated with age (P < .001) and LDH (P < .001), while positively correlated with hemoglobin (P = .041). After controlling for confounders, a one‐unit increase in ADAMTS13/VWF:Ag ratio was associated with 20% decreased odds of severe AKI. CONCLUSION: A low ADAMTS13 activity:VWF:Ag ratio at ED presentation is associated with progression to severe COVID‐19 disease and severe AKI, with a pattern suggestive of a secondary microangiopathy. Further interventional studies should be conducted to assess the restoration of ADAMTS13:VWF:Ag ratio in hospitalized patients with COVID‐19.

Coronavirus disease 2019 , the respiratory and systemic illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is clearly associated with coagulopathy, now termed COVID-19-associated coagulopathy (CAC). 1 The severity of CAC correlates with severity of COVID-19 illness and manifests clinically as arterial and venous thromboembolism, especially in critically ill patients. 1 On routine laboratory assessment, CAC is typically associated with moderately increased D-dimer values, mild thrombocytopenia, and modestly prolonged prothrombin time (PT). 2, 3 CAC is thought to be sustained via a combination of direct cytopathic endothelial injury by SARS-CoV-2, as well as hyperinflammation leading to immunothrombosis. 4 However, the exact mechanisms underlying

CAC have yet to be fully elucidated.

Recent evidence has pointed to the substantial possibility of a thrombotic microangiopathy (TMA)-like phenomenon, secondary to SARS-CoV-2 infection. 5 Recent laboratory studies have reported a relative ADAMTS13 deficiency in patients hospitalized with COVID- 19 , along with elevations in lactate dehydrogenase (LDH) and serum creatinine (SCr), with decreases in hemoglobin and platelets. 2, 5 When combined with clinical and pathologic findings of acute kidney injury (AKI), lung injury, and cardiac injury, this becomes suggestive of a TMA-like picture, as opposed to disseminated intravascular coagulopathy (DIC). [6] [7] [8] ADAMTS13, also known as "a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13" or "von Willebrand factor-cleaving protease," is a liver-generated enzyme, which cleaves large von Willebrand factor (VWF) multimers in blood. 9 In COVID-19, elevated levels of VWF have been reported, which is likely due to a combination of endothelial injury and its release as an acute phase reactant. 9,10 Low ADAMTS13 activity, due to consumption or inflammation-mediated degradation, may result in accumulation of ultralarge VWF multimers that may then interplay with platelets to cause microthrombosis and trigger immunothrombosis. 4, 8 Thus, the presence of low ADAMTS13 coupled with high VWF may represent a "double insult" leading to a heightened state of hypercoagulability, and also to a TMA-like phenomenon, first localized to lung, but eventually spreading systematically, leading to end-organ damage.

Huisman et al 9 reported a disproportionately high level of VWF antigen (VWF:Ag) to ADAMTS13 level in a case series of 12 COVID-19 patients with suspected TMA, while Bazzan et al, 11 in a series of 88 COVID-19 patients, found low ADAMTS13 levels to be a predictor of mortality.

However, to the best of our knowledge, no study has investigated the direct relationship between the ADAMTS13 and VWF axis with respect to outcomes in COVID-19 patients. Therefore, the aim of this investigation was to study this relationship, exploring ADAMTS13 activity/VWF:Ag ratio measured at emergency department presentation and COVID-19 clinical outcomes, specifically severe AKI and COVID-19 severity, as well as to correlate this ratio with other biochemical markers of TMA. Given that renal injury is the most common manifestation of TMA, as commonly associated with multi-organ dysfunction syndrome, impairment of innate immunity, and increased mortality risk among critically ill patients, 12 severe AKI was chosen as the primary endpoint of this study. 

Patient blood samples were collected during the index ED visit via a clinically routine blood collection. All laboratory analyses were 

The complete blood cell count (CBC) with differential was performed using a Beckman Coulter UniCel DxH 800 Cellular Analysis System on EDTA-collected blood. Serum creatinine was measured using a kinetic alkaline picrate (modified Jaffe) method on either a Beckman Coulter AU480 Chemistry Analyzer or a Beckman Coulter DiaPharma Group Inc). A VWF:Ag level of >215 U/dL was considered elevated. 13 ADAMTS13 activity was measured using a fluorescence resonance energy transfer (FRET) assay (Immucor, Inc). An ADAMTS13 activity level of >67% was defined as normal activity.

All assays were performed according to manufacturers' instructions and guidance. 

The primary outcome was development of AKI during the COVID-19 course of illness defined as Kidney Disease Improving Global Outcomes (KDIGO) Stage 2 and 3 evaluated using SCr criteria. 14 When a previous SCr value prior to COVID-19 illness was not available, the lowest SCr during the 30-day follow-up was used for evaluating AKI over the course of illness.

The secondary outcome was progression to severe COVID-19 during hospitalization or within 30 days of index ED presentation.

Patient severity was first evaluated using an 8-point ordinal scale as outlined by the World Health Organization (WHO) R&D Blueprint, 15 which allowed to classify patients into two severity groups: mild/ moderate (ordinal scale 1-4) or severe (ordinal scale 5-8) illness.

Categorical variables were reported as absolute number (n) and relative frequency (%), while continuous variables were reported as median and interquartile range (IQR). Categorical variables were compared using the chi-squared test (χ 2 ) or Fisher's exact test, as appropriate, based on expected accounts. Continuous variables were compared using the nonparametric Mann-Whitney U test, while comparisons of multiple continuous variables were analyzed using Kruskal-Wallis one-way analysis of variance. Correlations between variables were performed using Spearman's correlation. Multivariable logistic regression was employed to identify if ADAMTS13/VWF:Ag ratio and baseline variables were independent predictors of the primary and secondary outcomes. All baseline patient characteristics (excluding laboratory values) from Table 1 with a P-value of <.10 were included in the model, and relevant variable selection was performed using a bidirectional stepwise algorithm. Adjusted odds ratios (ORs) and 95% confidence intervals (95% CIs) were computed. Statistical analysis was performed using Prism 8 (GraphPad Software) and R (version 4.0.2; R Foundation for Statistical Computing) with a P < .05 considered statistically significant. Table 1 . Patients who developed severe AKI were older (P = .003) and disproportionality black as opposed to white or his panic (P = .042). Moreover, higher rates of coronary artery disease (P = .015), heart failure (P = .003), hypertension (P = .002), chronic kidney disease (P = .002), chronic liver disease (P = .041), and cancer (P = .034) were observed in those who developed severe AKI. Interestingly, patients who were current smokers (P = .003) but not former smokers (P = .421) were observed to have higher rates of severe AKI during course of illness. In patients who developed severe AKI, procalcitonin (P < .001), ferritin (P = .017), myoglobin (P < .001), and LDH (P = .039) were significantly elevated, while hemoglobin was significantly lower (P = .013).

No difference was found for D-dimer (P = .289), PT (P = .672) or platelet count (P = .924).

The levels of ADAMTS13 and VWF:Ag and their ratio stratified by AKI are shown in Table 2 . ADAMTS activity was found to be 35% lower in patients with severe AKI (P = .005), while VWF:Ag was 67.5 U/ dL higher in patients with severe AKI, albeit this difference did not reach statistical significance (P = .062). A total of 12 patients (23.1%) TA B L E 1 Patient demographics and baseline characteristics at index ED visit by presence or absence of severe acute kidney injury Levels of ADAMTS13 and VWF:Ag and their ratio by peak 30-day COVID-19 severity are shown in Table 3 . ADAMTS13 trended lower in patients progressing to severe disease (P = .005), while VWF:Ag was not significantly different between groups (P = .463). The ADAMTS13/ VWF:Ag ratio trended lower with disease severity, with patients with severe disease having a significantly lower ratio compared to those with mild/moderate disease (P = .020). ( Figure 1B) . A further analysis comparing these variables between a more detailed clinically defined cohort (mild vs moderate vs severe) is available in Table S1 . 

The results of multivariate logistic regression are presented in 

In this prospective, observational study of 52 laboratory-confirmed COVID-19 patients we found that low ADAMTS13/VWF:Ag ratio Interestingly, ADAMTS13:VWF:Ag ratio was negatively correlated with age, which may be partly explained by expected trends observed with advancing age. Kokame et al 17 reported that ADAMTS13 activity decreases with age, especially after 60 years, while plasma VWF:Ag levels increase in the elderly, thus resulting in significant changes in their ratio (increase in VWF/ADAMTS13 ratio, or decrease in ADAMTS13/VWF ratio). Such changes likely contribute to a prothrombotic state with advancing age, potentially contributing to pathologies such as myocardial infarction and stroke. 17 Similarly, we hypothesize that such changes may contribute to COVID-19 severity and in part explain higher morbidity and mortality in elderly patients. Thus, elderly patients with lower baseline ADAMTS13 activity, but higher VWF levels, may not be able to compensate for the inflammation-driven release of large VWF multimers, leading to faster and/or enhanced accumulation of microthrombi within the lungs. Given the possibility for age to confound the primary analysis due to multiple factors, we explored advancing age as an independent predictor of severe AKI in multivariate analysis; however, it was not significant when controlling for other variables.

The ADAMTS13:VWF:Ag ratio was also found to be negatively correlated with LDH, while positively correlated with hemoglobin. These correlations further paint a picture of a secondary 

We found that low ADAMTS13:VWF:Ag ratio at ED presentation is associated with an increased risk of progressing to critical COVID-19 illness and severe AKI, with a pattern suggestive of a secondary microangiopathy. Nearly, a fourth of our patients presented with relative deficiency in ADAMTS13 activity, while 80.8% had elevated levels of VWF:Ag. The ADAMTS13:VWF:Ag ratio correlated with age, reinforcing evidence that patients with advanced age may be more susceptible to thrombotic complications and unfavorable outcome in COVID-19. Interventional studies should be conducted to assess the benefit of restoring ADAMTS13:VWF:Ag ratios in hospitalized patients with COVID-19.

The authors declare no conflict of interest. 

COVID-19: unravelling the clinical progression of nature's virtually perfect biological weapon

Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Hyperinflammation and derangement of renin-angiotensin-aldosterone system in COVID-19: a novel hypothesis for clinically suspected hypercoagulopathy and microvascular immunothrombosis

A relative ADAMTS13 deficiency supports the presence of a secondary microangiopathy in COVID 19

Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19

Severe COVID-19 infection and thrombotic microangiopathy: success does not come easily

Coronavirus disease 2019 coagulopathy: disseminated intravascular coagulation and thrombotic microangiopathy-either, neither, or both

Involvement of ADAMTS13 and von Willebrand factor in thromboembolic events in patients infected with SARS-CoV-2

Von Willebrand factor (vWF): marker of endothelial damage and thrombotic risk in COVID-19

Low ADAMTS 13 plasma levels are predictors of mortality in COVID-19 patients

AKI in the ICU: definition, epidemiology, risk stratification, and outcomes

ARUP Laboratories. von Willebrand factor antigen reference interval

KDIGO clinical practice guideline for acute kidney injury

WHO R&D Blueprint novel coronavirus: COVID-19 theapeutic trial synposis

Role of von Willebrand factor and ADAMTS-13 in the pathogenesis of thrombi in SARS-CoV-2 infection: time to rethink

von Willebrand factor-to-ADAMTS13 ratio increases with age in a Japanese population

Linear relationship between ADAMTS13 activity and platelet dynamics even before severe thrombocytopenia

Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a meta-analysis

Acute kidney injury is associated with worse prognosis in COVID-19 patients: a systematic review and meta-analysis

Multiorgan and renal tropism of SARS-CoV-2

SARS-CoV-2 renal tropism associates with acute kidney injury

Decreased ADAMTS 13 activity is associated with disease severity and outcome in pediatric severe sepsis

ADAMTS-13, von Willebrand factor and related parameters in severe sepsis and septic shock

Pulmonary embolism or pulmonary thrombosis in COVID-19? Is the recommendation to use high-dose heparin for thromboprophylaxis justified?

Plasma exchange in critically ill COVID-19 patients

Therapeutic plasma exchange in adults with severe COVID-19 infection